Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Motyl

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Jac-Antimicrobial Resistance|January 1, 2024
Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21James A Karlowsky, Mark G Wise, Wei-Ting Chen, et al.
Journal of Clinical Microbiology|March 17, 2017
<i>In Vitro</i> Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014James A Karlowsky, Sibylle H Lob, Krystyna M Kazmierczak, et al.
Antimicrobial Agents and Chemotherapy|February 8, 2017
Global Molecular Epidemiology of IMP-Producing EnterobacteriaceaeYasufumi Matsumura, Gisele Peirano, Mary R Motyl, et al.
Open Forum Infectious Diseases|July 26, 2021
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of <i>Pseudomonas aeruginosa</i> From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019Sibylle H Lob, Daryl D DePestel, C Andrew DeRyke, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2017
<i>In Vitro</i> Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)Sibylle H Lob, Meredith A Hackel, Krystyna M Kazmierczak, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 20, 2023
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020Sibylle H Lob, Stephen P Hawser, Fakhar Siddiqui, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|May 11, 2023
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2014
Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh modelEleftheria Mavridou, Ria J B Melchers, Anita C H A M van Mil, et al.
Jac-Antimicrobial Resistance|May 27, 2024
Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 16, 2022
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020Sibylle H Lob, Mark A Estabrook, C Andrew DeRyke, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Jac-Antimicrobial Resistance|January 1, 2024
Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21James A Karlowsky, Mark G Wise, Wei-Ting Chen, et al.
Journal of Clinical Microbiology|March 17, 2017
<i>In Vitro</i> Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014James A Karlowsky, Sibylle H Lob, Krystyna M Kazmierczak, et al.
Antimicrobial Agents and Chemotherapy|February 8, 2017
Global Molecular Epidemiology of IMP-Producing EnterobacteriaceaeYasufumi Matsumura, Gisele Peirano, Mary R Motyl, et al.
Open Forum Infectious Diseases|July 26, 2021
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of <i>Pseudomonas aeruginosa</i> From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019Sibylle H Lob, Daryl D DePestel, C Andrew DeRyke, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2017
<i>In Vitro</i> Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)Sibylle H Lob, Meredith A Hackel, Krystyna M Kazmierczak, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 20, 2023
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020Sibylle H Lob, Stephen P Hawser, Fakhar Siddiqui, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|May 11, 2023
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2014
Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh modelEleftheria Mavridou, Ria J B Melchers, Anita C H A M van Mil, et al.
Jac-Antimicrobial Resistance|May 27, 2024
Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 16, 2022
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020Sibylle H Lob, Mark A Estabrook, C Andrew DeRyke, et al.
Pageof 8